A Phase I Trial of Sirolimus (mTOR Inhibitor) or Vorinostat (HDAC Inhibitor) in Combination with Hydroxychloroquine (Autophagy Inhibitor) in Patients with Advanced Malignancies
MD Anderson Study Status
Hydroxychloroquine, Sirolimus, Vorinostat
The goal of this clinical research study is to find the highest tolerable dose of sirolimus or vorinostat that can be given in combination with hydroxychloroquine to patients with advanced cancer. The safety of these drug combinations will also be studied.
Information and next steps
Investigational Cancer Therapeutics
For general questions about clinical trials: